Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

L. Kwak, Eunice; Bang, Yung‐Jue; Ross Camidge, D.; T. Shaw, Alice; Solomon, Benjamin; G. Maki, Robert; Ignatius Ou, Sai‐Hong; J. Dezube, Bruce; A. Jänne, Pasi; B. Costa, Daniel; Varella‐Garcia, Marileila; Ho Kim, Woo; J. Lynch, Thomas; Fidias, Panos; Stubbs, Hannah; A. Engelman, Jeffrey; V. Sequist, Lecia; Tan, Weiwei; Gandhi, Leena; Mino–Kenudson, Mari; C. G. Wei, Greg; Martin Shreeve, S.; J. Ratain, Mark; Settleman, Jeffrey; G. Christensen, James; A. Haber, Daniel; D. Wilner, Keith; Salgia, Ravi; I. Shapiro, Geoffrey; W. Clark, Jeffrey; John Iafrate, A.

doi:10.1056/nejmoa1006448

Public

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Oct 27, 2010

Authors:

Eunice L. Kwak

Yung‐Jue Bang

D. Ross Camidge

Abstract

BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotin...

Subject

Crizotinib

Anaplastic lymphoma kinase

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!